Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.17 (
MMP-3
)
3,419
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated whether
PF4
could regulate the constitutive and thrombin-stimulated expression of metalloproteinases (MMPs) in endothelial cells (EC).
PF4
inhibited the increase in the expression of MMP-1 and
MMP-3
promoted by thrombin or the thrombin receptor agonist peptide SFLLRNPNDKYEPF (SFLL..) by 50% but did not modify the constitutive expression of these MMPs. This inhibitory effect was not mediated through a direct interaction of
PF4
with thrombin or with the MMPs themselves. The interaction of
PF4
with heparan sulfates at the surface of the EC appeared to be implicated in the inhibition mechanism of MMP-1 but not in that of
MMP-3
. MMP-1 transcription levels remained unchanged after
PF4
treatment, whereas the increase in
MMP-3
transcription induced by thrombin or SFLL.. was inhibited by approximately 50%. Expression of the tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 was not affected by
PF4
. The present data provide new evidence that the antiangiogenic properties of
PF4
involve the inhibition of matrix breakdown and suggest that this property of
PF4
could be especially relevant in the context of thrombin-regulated tissue remodelling.
...
PMID:PF4 inhibits thrombin-stimulated MMP-1 and MMP-3 metalloproteinase expression in human vascular endothelial cells. 949 37
